Lymphoma Clinical Trials

Showing 881-900 of 2,926 trials

A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL

NCT04841434

This phase I-II trial is intented to demonstrate tolerability (i.e. absence of severe non-hematological toxicity) and efficacy of intended intervention with repeated doses of Voraxaze, in addition to leucovorin (LV), in patients with renal impairment or renal failure during previous HD-MTX therapy. Patients will receive up to 6 cycles of HD-MTX treatment with 14 days between cycles (a maximum delay of 28 days is permitted in order to allow time for a patient to recover from the previous cycle).

CNS Lymphoma

Charite University, Berlin, Germany18 participantsStarted Jun 2021

Berlin, Germany

RECRUITINGEARLY Phase 1

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

NCT06756321

This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.

Relapsed/refractory LymphomaRelapsed/Refractory Leukemia

Affiliated Hospital of Nantong University9 participantsStarted Sep 2023

Nantong, Jiangsu, China

A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Related Searches

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Dynamic CtDNA-guided Targeted Therapy in DLBCL

Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

VHAG in Treating R/R T-ALL/LBL

Real-World Study of DLBCL With Different Genetic Subtypes

Intratumoral CAN2109 in Subjects With Solid Tumors

Allo-HSCT vs ASCT in Adult T-LBL

Golidocitinib Plus CHOP in Newly Diagnosed PTCL

Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma